Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

The pharmacokinetics and metabolism of BIBF 1120, an oral triple angiokinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), were studied in healthy male volunteers (n == 8) who had received a single oral dose of 100 mg [